Furthermore, DR5-triggering of mouse DCs by TRAIL+ cNK/ILC1s reduced their cross-presentation and -priming capacity for tumor-antigens, leading to reduced anti-tumor T cell responses [106]. Here, TNFRSF10B is linked to neoplasm.